CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 288,736.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 811,630 shares of the biotechnology company’s stock after purchasing an additional 811,349 shares during the period. JPMorgan Chase & Co. owned 1.04% of CytomX Therapeutics worth $836,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in CytomX Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after buying an additional 34,032 shares during the last quarter. Monimus Capital Management LP bought a new position in shares of CytomX Therapeutics during the fourth quarter worth about $375,000. Virtu Financial LLC bought a new position in shares of CytomX Therapeutics during the third quarter worth about $104,000. Prudential Financial Inc. lifted its position in shares of CytomX Therapeutics by 76.2% during the fourth quarter. Prudential Financial Inc. now owns 64,300 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 27,800 shares during the last quarter. Finally, Traphagen Investment Advisors LLC acquired a new stake in CytomX Therapeutics during the fourth quarter worth about $31,000. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Stock Down 0.3 %

CytomX Therapeutics stock opened at $0.71 on Tuesday. CytomX Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $5.85. The business has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $0.87. The stock has a market cap of $56.70 million, a price-to-earnings ratio of 4.16 and a beta of 1.34.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The firm had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. On average, analysts expect that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CTMX shares. HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. StockNews.com assumed coverage on CytomX Therapeutics in a research report on Tuesday, April 15th. They set a “hold” rating for the company. Piper Sandler began coverage on CytomX Therapeutics in a research report on Monday, April 14th. They issued an “overweight” rating and a $2.50 price target for the company. Finally, Wedbush restated an “outperform” rating and issued a $5.00 price target on shares of CytomX Therapeutics in a research report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, CytomX Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $4.77.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.